ENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of January 6, 2017

NEW YORK, Dec. 09, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Endo International plc ENDP securities between September 28, 2015 and November 2, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/endo-international. There is no cost or obligation to you.

According to the complaint, during the Class Period, Defendants failed to disclose that: (i) Endo's subsidiary, Par Pharmaceutical, had colluded with several of its industry peers to manipulate the prices of generic drugs; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Endo's revenues during the Class Period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Endo's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Endo International you have until January 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endo-international.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.